GlassScriptPhysician profile
Preston Y Kim
NPI 1194715391
$17,830.77
in general payments reported to CMS, 2019-2025
51 companies · $3,906 in 2025
The $3,906 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $1,687 · 2021: $2,153 · 2022: $2,369 · 2023: $2,429 · 2024: $3,189 · 2025: $3,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,447 · Education: $77.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,447.08 |
| Education | $77.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,462.40 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,407.52 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $2,270.46 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,962.19 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $1,045.10 | 2019-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $769.25 | 2022-2025 | Ibsrela |
| Pfizer INC. | $699.21 | 2019-2025 | |
| Celgene Corporation | $627.99 | 2021-2024 | Zeposia |
| Genzyme Corporation | $554.42 | 2022-2025 | |
| Madrigal Pharmaceuticals | $442.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $374.33 | 2020-2023 | |
| Daiichi Sankyo INC. | $294.80 | 2019-2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $262.31 | 2019-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $249.40 | 2022-2024 | Dupixent |
| Redhill Biopharma INC. | $238.12 | 2020-2023 | Talicia, Movantik, Aemcolo |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $227.49 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Ironwood Pharmaceuticals, INC | $224.96 | 2020-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $202.01 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $167.45 | 2024-2025 | Zenpep |
| Amgen INC. | $163.90 | 2020-2023 | Amjevita, Avsola |
| Organon LLC | $161.91 | 2021-2025 | Hadlima, Renflexis |
| Celltrion USA INC. | $156.40 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $147.84 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $135.64 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $133.07 | 2024-2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $131.63 | 2023-2025 | Monoferric |
| Allergan, INC. | $131.27 | 2019-2020 | |
| Boston Scientific Corporation | $125.52 | 2019-2024 | Compliance Endokit, Resolution Clip, Cre Pro |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $112.30 | 2024-2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $110.00 | 2022 | |
| Merck Sharp & Dohme LLC | $109.06 | 2019-2024 | Dificid, Zinplava |
| Romark Laboratories, Lc | $79.31 | 2019-2020 | |
| Novo Nordisk INC | $55.41 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $47.49 | 2022-2025 | Givlaari |
| Amag Pharmaceuticals, INC. | $44.11 | 2019-2022 | |
| Micro-Tech Endoscopy USA, INC. | $40.00 | 2024-2025 | Lockado |
| Enterra Medical, INC. | $38.37 | 2025 | |
| Endo Pharmaceuticals INC. | $38.32 | 2020 | |
| Exact Sciences Corporation | $36.35 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $33.48 | 2024 | Terlivaz |
| Gilead Sciences, INC. | $31.53 | 2019-2021 | |
| Evoke Pharma, INC. | $30.97 | 2021-2025 | |
| Caris Mpi, INC. | $29.40 | 2025 | Mi Cancer Seek |
| Digestive Care, INC. | $17.36 | 2021 | |
| Shire North American Group INC | $17.35 | 2019 | |
| Eagle Pharmaceuticals, INC. | $14.65 | 2024 | |
| Ucb, INC. | $14.48 | 2019 | |
| Vivus LLC | $14.31 | 2019 | |
| Meridian Bioscience INC. | $11.96 | 2023 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preston Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.